1 citations
,
September 2024 in “International Journal of Advanced Multidisciplinary Research and Studies” This study observed that 100% of cancer patients at Dr. Moewardi Surakarta Hospital receiving carboplatin-paclitaxel chemotherapy experienced grade 2 alopecia as an adverse drug reaction.
5 citations
,
January 2024 in “BMC Cancer” In this descriptive study, researchers assessed the most common short-term side effects of anthracycline and taxane-based chemotherapy in 122 Moroccan women with localized breast cancer, documenting frequent systemic, gastrointestinal, dermatological, neurological, musculoskeletal, and ocular toxicities.
November 2024 in “Scientific Reports” In this study, researchers at a tertiary cancer center observed that many male germ cell tumor survivors experienced degrees of hypogonadism and erectile dysfunction, highlighting the clinical need to monitor endocrine health in cancer survivors.
February 2024 in “Frontiers in Cell and Developmental Biology” This study found that eribulin-based chemotherapy resulted in longer median progression-free and overall survival, with fewer side effects, for advanced triple-negative breast cancer patients compared to other chemotherapy options.
May 2019 in “Journal of clinical oncology” This Phase 1 study reported that topical application of BPM31543 was safe and well-tolerated in patients receiving taxane-based chemotherapy, with some experiencing less than 50% hair loss, suggesting potential efficacy in reducing chemotherapy-induced alopecia, although no maximum tolerated dose was identified.